You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Brexanolone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for brexanolone and what is the scope of patent protection?

Brexanolone is the generic ingredient in one branded drug marketed by Sage Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brexanolone has one hundred and twenty-three patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for brexanolone
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brexanolone
Generic Entry Date for brexanolone*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for brexanolone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brii Biosciences LimitedPhase 1
Sage TherapeuticsPhase 2
Brigham and Women's HospitalPhase 4

See all brexanolone clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for brexanolone

US Patents and Regulatory Information for brexanolone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for brexanolone

Country Patent Number Title Estimated Expiration
Israel 276403 תכשירים פרמצבטיים הכוללים אלופרגננולון (Pharmaceutical compositions comprising allopregnanolone) ⤷  Sign Up
European Patent Office 4295908 FORMULATIONS STÉROÏDIENNES NEUROACTIVES COMPRENANT UN COMPLEXE D'ALLOPRÉGNANOLONE ET D'ÉTHER SULFOBUTYLIQUE BÊTA-CYCLODEXTRINE (NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN) ⤷  Sign Up
New Zealand 773177 Neuroactive steroid formulations and methods of treating cns disorders ⤷  Sign Up
Taiwan I798173 ⤷  Sign Up
China 114053423 磺烷基醚环糊精组合物 (Sulfoalkyl ether cyclodextrin compositions) ⤷  Sign Up
Australia 2017229656 Neuroactive steroids, compositions, and uses thereof ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.